((自动化翻译由路透提供，请见免责声明 ))
10月22日 - ** 基因组医疗公司Sangamo Therapeutics 股价盘前上涨6%至96美分
** 该公司表示，美国食品和药物管理局（FDA）已同意将正在进行的早中期研究数据作为加速批准其治疗法布里病的实验性基因疗法的主要依据
** 法布里病是一种遗传性疾病，由人体细胞中的一种脂肪堆积引起。
** 不需要额外的注册研究来支持基因疗法isaralgagene civaparvovec的加速审批--SGMO公司
** SGMO公司称，2025年上半年将获得完整的研究数据集，预计2025年下半年提交申请。
** 截至上次收盘，股价年累计上涨68
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.